¿Soy candidato para la cirugía para bajar de peso? Qué se necesita para calificar

Here's something that should bother you. The criteria your insurance company uses — right now, to decide whether you qualify for weight loss surgery... were written in 1991. Thirty-five years ago.

And the studies those criteria were based on? Those are from the 1960s, the '70s, the '80s. We're talking about data that is 45 to 60 years old. Back when these surgeries were done through massive open incisions. Before laparoscopy. Before we even really understood what metabolic surgery could do.

And here's the part that really gets me. The NIH — the National Institutes of Health — the very organization that wrote those criteria — has a disclaimer on their own website. And I'm paraphrasing here, but it basically says: "This statement is more than five years old. It is provided solely for historical purposes. Some of the material is likely out of date, and at worst... simply wrong."

That's not me saying that. That's them. The people who wrote it. And yet... insurance companies still use those criteria to deny people life-changing — and in many cases, life-saving — surgery. Every single day.

So today, we're going to walk through exactly how we got here. How the criteria were created, who created them, why they haven't been updated in 35 years, what the new guidelines actually say, and where we're headed in the future. Because if you're trying to understand whether you — or someone you love — is a candidate for bariatric surgery... you deserve to know the full story. Let's get into it.

Where the Criteria Came From: 1991

Alright. Let's go back to 1991. To understand why these criteria exist, you have to understand what was happening in the world of bariatric surgery at that time. And honestly? It wasn't great.

In the decades before 1991, some of the early weight loss operations — like the jejunoileal bypass — had turned out to be disasters. Patients were developing liver failure, kidney stones, severe malnutrition. Some were dying. And the medical community — understandably — had largely turned against the idea of surgery for obesity.

But here's the thing. Obesity wasn't going away. It was getting worse. And the non-surgical treatments — the diets, the medications available at the time — they just weren't working for people with severe obesity. Not long-term.

So the field needed something. It needed structure and standards. It needed someone to say: "Here's who should get surgery, here's who shouldn't, and here's how it should be done." That's where the NIH stepped in.

In March of 1991 — March 25th through the 27th — the National Institutes of Health held what's called a Consensus Development Conference. Now, this is a specific format the NIH uses. They bring together a panel of experts, they hear two days of presentations, the audience discusses, and then the panel goes behind closed doors and writes a consensus statement.

The panel was multidisciplinary. They had surgeons, gastroenterologists, endocrinologists, psychiatrists, nutritionists, other healthcare professionals, and even members of the general public. Which sounds great on paper.

But here's what's important to understand. The panel was heavily weighted toward non-surgeons. Out of the entire panel, only a very small number — we're talking one, maybe two — were bariatric surgeons who actually performed these operations on a regular basis. The rest were internists, psychiatrists, public representatives, and other specialists who didn't operate on these patients.

Now, I'm not saying non-surgeons shouldn't have a voice. Of course they should. But imagine if we wrote the guidelines for cardiac surgery and only had one heart surgeon in the room. You'd want the people who actually do the work to have a meaningful seat at the table.

And then there's the evidence they had to work with. Which was... limited. Very limited.

This was 1991. There were no large randomized controlled trials comparing surgery to medical therapy for obesity. None. The studies that existed were mostly small case series and a handful of trials comparing one surgical technique to another — like gastric bypass versus gastroplasty. And those studies were published in the 1970s and 1980s. So even in 1991, the data was already 10 to 20 years old. Today? That same data is 45 to 60 years old.

The published consensus statement itself — which came out in the Annals of Internal Medicine in 1991 and the American Journal of Clinical Nutrition in 1992 — is a brief document. It's not a systematic review. It's not a deep dive into hundreds of studies. It's a short consensus statement based on expert opinion and a limited body of literature.

So what did it actually say? Here are the key points. First: surgery could be considered for patients with a BMI of 40 or higher. That's about 100 pounds overweight, give or take, depending on your height.

Second: surgery could also be considered for patients with a BMI of 35 or higher — but only if they had serious obesity-related health problems. Things like diabetes, sleep apnea, high blood pressure, severe joint disease. Third: patients should first try non-surgical treatment. Diet, exercise, behavior modification, psychological support.

Fourth: surgery should be done by experienced surgeons in appropriate clinical settings. Fifth: patients need lifelong medical follow-up after surgery. And sixth — and this is important — only two procedures were endorsed. Roux-en-Y gastric bypass and vertical banded gastroplasty. That's it. Those were the only two operations they said were acceptable.

Now here's the kicker. Vertical banded gastroplasty — the VBG — has been completely abandoned. It disappeared from clinical practice over a decade ago because the long-term results were, frankly, disappointing. And sleeve gastrectomy — which is now the most commonly performed bariatric procedure in the entire world — didn't even exist yet. It wasn't even a concept.

So let me just put that in perspective. The criteria that still govern who gets bariatric surgery today... endorsed a procedure that no one does anymore... and didn't include the procedure that everyone does now. But despite all of that, the 1991 consensus statement did something incredibly important. Before it existed, there was no standard. No framework. No agreed-upon criteria for who should get surgery and who shouldn't. It was the Wild West.

The NIH statement changed that. It legitimized bariatric surgery as a discipline. It gave surgeons, hospitals, and insurance companies a framework to work with. The problem is... insurance companies latched onto that framework. And they never let go.

Why the Criteria Were Never Updated

So here's the obvious question. If the 1991 criteria are based on limited evidence from the era of open surgery... and the NIH itself says they're outdated... why hasn't anyone updated them? It's a fair question. And the answer is frustrating.

Let me start with what the NIH itself says. On their website, for any consensus statement that's more than five years old, they post a disclaimer. And it reads — and this is close to a direct quote: "This statement is more than five years old and is provided solely for historical purposes. Due to the cumulative nature of medical research, new knowledge has inevitably accumulated in this subject area. Thus, some of the material is likely to be out of date, and at worst simply wrong."

At worst simply wrong. And yet, no updated NIH consensus conference on bariatric surgery has ever been held. Not in 1995. Not in 2000. Not in 2010. Not in 2020. Never.

Why not?

Well, part of it is how the NIH works. They generally want a substantial body of what's called Level 1 evidence — meaning large randomized controlled trials — before they'll convene a new consensus conference. And for years after 1991, the randomized trials that did exist in bariatric surgery compared one operation to another. Gastric bypass versus gastroplasty. Gastric bypass versus gastric banding. They didn't compare surgery to medical management — which is really the question the guidelines are supposed to answer.

Part of it is also just institutional inertia. The 1991 statement "worked" — in the sense that it gave everyone a framework. Insurance companies used it. Hospitals used it. And nobody inside the NIH pushed hard enough to revisit it.

But meanwhile — while the criteria sat frozen in 1991 — the field of bariatric surgery evolved beyond recognition. Think about what changed.

In the late 1990s and early 2000s, laparoscopic surgery took over. We went from massive open incisions to tiny keyhole incisions. And that didn't just make recovery easier — it made the surgery dramatically safer. Operative mortality dropped by a factor of ten. lets me say that again, it is now more than Ten times safer.

Today, the perioperative mortality rate for bariatric surgery is somewhere between 0.03% and 0.2%. To put that in context — that's lower than the mortality rate for a gallbladder removal. Lower than a hip replacement. Lower than a knee replacement. We're talking about one of the safest operations in all of surgery.

Vertical banded gastroplasty disappeared. Sleeve gastrectomy emerged and became the most popular procedure in the world. Adjustable gastric banding came and went. Gastric bypass was refined and made safer and more effective.

Fellowship training programs were established. Centers of Excellence were created. Quality registries were built. The entire infrastructure of the field was professionalized.

And then — finally — the randomized controlled trials that the NIH had been waiting for started to come in. And they showed something remarkable. When you compared bariatric surgery to the best available medical therapy for type 2 diabetes... surgery won. Decisively. Not just for weight loss — for diabetes remission, for cardiovascular risk reduction, for long-term survival.

But through all of that — all of those advances, all of that evidence — the criteria stayed frozen In 1991. And the cost of that inaction has been enormous. Insurance companies anchored to the 1991 criteria because it was the only "official" government-endorsed guideline. Patients with a BMI of 30 to 35 who had severe metabolic disease — people who would clearly benefit from surgery — were systematically excluded.

And access to bariatric surgery remains shockingly low. Depending on which study you look at, somewhere between 0.5% and 1% of eligible patients actually receive surgery. Let me say that again. Out of every 100 people who qualify for and would benefit from bariatric surgery... one of them actually gets it.

That's not a healthcare system working. That's a healthcare system failing

The 2022 Guidelines: A Modern Standard

So if the NIH wasn't going to update the criteria... someone else had to. And in 2022, someone did.

The two largest metabolic and bariatric surgery organizations in the world — the American Society for Metabolic and Bariatric Surgery, or ASMBS, and the International Federation for the Surgery of Obesity and Metabolic Disorders, or IFSO — came together and said: enough. It's been over 30 years. The 1991 guidelines are based on expert opinion from the era of open surgery. They don't reflect the current evidence. They don't reflect the current state of the field. It's time for new guidelines.

And they did it right. Let me walk you through how these guidelines were created, because the process matters. It matters a lot. Especially when you compare it to how the 1991 criteria were made.

The authorship group included approximately 24 contributors from multiple countries. These were surgeons, endocrinologists, and other obesity medicine specialists. Unlike the 1991 NIH panel — which was heavily weighted toward non-surgeons — this group was led primarily by metabolic and bariatric surgeons who actually practice in the field. People who operate on these patients every day. But it also included non-surgeon obesity specialists, so it wasn't just surgeons talking to surgeons.

They used something called the PRISMA methodology — that stands for Preferred Reporting Items for Systematic Reviews and Meta-Analyses. It's a rigorous, standardized approach to reviewing evidence. This isn't a group of people sitting in a room sharing opinions. This is a systematic, transparent review of the published literature.

They performed systematic reviews on 13 specific topics. Thirteen. And for each topic, they graded the strength of the evidence and the strength of the recommendation.

Where high-quality literature was available — which was most of the time — they used it. Eleven of the 13 criteria were directly supported by published studies. For the two topics where the literature was lacking, they used a Delphi survey — which is a structured process where global experts vote anonymously in multiple rounds until they reach consensus.

The supporting evidence paper — published by De Luca, Shikora, Eisenberg, and colleagues in 2024 — reviewed hundreds of studies spanning from the 1990s through the early 2020s. Hundreds. Compare that to the handful of studies from the 1970s and '80s that the 1991 panel had to work with. It's not even close.

So what do the new guidelines actually say? Let me walk you through the major changes, because they're significant.

Number one. BMI of 35 or higher — surgery is recommended regardless of whether you have any other health problems or not. This is a big change. Under the old 1991 criteria, if your BMI was between 35 and 40, you needed to have comorbidities — diabetes, sleep apnea, high blood pressure — to qualify. Now? You don't. A BMI of 35 or above is enough on its own.

Number two. BMI of 30 to 35 — surgery should be considered if you have metabolic disease. Especially type 2 diabetes that isn't well controlled with medications. This opens the door for an entirely new population of patients who were previously excluded.

Number three. Asian populations. The guidelines now recognize that BMI thresholds should be adjusted downward for people of Asian descent. A BMI over 25 suggests clinical obesity in Asian populations, and individuals with a BMI over 27.5 should be offered surgery. This is based on strong evidence that Asian populations develop metabolic complications at lower BMI levels.

Number four. Age. The 1991 criteria said there was "no data available" for adolescents or people over 70. The new guidelines expand to include both. Adolescents can now be considered for surgery. And patients over 70 can be considered after careful evaluation of risks and benefits.

Number five. Pediatric criteria — and I'll go into more detail on this later — but the guidelines now include specific criteria for adolescents. BMI at or above 120% of the 95th percentile for age with related medical problems. Or BMI at or above 140% of the 95th percentile without requiring comorbidities.

Number six. Special situations. The new guidelines recognize that surgery can serve as a bridge to other treatments — like joint replacement, abdominal wall hernia repair, or organ transplantation. These situations weren't even addressed in 1991.

Number seven. The recommended procedures have been updated. Roux-en-Y gastric bypass and sleeve gastrectomy are the two primary recommended procedures. Vertical banded gastroplasty — one of the two procedures endorsed in 1991 — is gone. Because nobody does it anymore.

And number eight. The guidelines affirm that the long-term results of metabolic and bariatric surgery consistently demonstrate both safety and efficacy.

1991 vs. 2022: Side by Side

Now let me put this side by side so you can really see the difference. Under the 1991 criteria: you needed a BMI of 40 or higher to qualify without comorbidities. Under the 2022 criteria: that threshold dropped to 35. Under the 1991 criteria: you needed a BMI of 35 with comorbidities. Under the 2022 criteria: you can qualify with a BMI of 30 if you have metabolic disease like uncontrolled diabetes.

Under the 1991 criteria: there was no adjustment for ethnicity. Under the 2022 criteria: Asian populations have lower thresholds. Under the 1991 criteria: adolescents and elderly patients were essentially excluded. Under the 2022 criteria: both are included.

Under the 1991 criteria: the endorsed procedures were gastric bypass and a procedure nobody does anymore. Under the 2022 criteria: the endorsed procedures are gastric bypass and sleeve gastrectomy — the two operations that actually dominate modern practice.

Under the 1991 criteria: the evidence base was expert opinion and a small number of studies from the 1960s through the 1980s. Under the 2022 criteria: the evidence base is systematic reviews using PRISMA methodology, drawing on hundreds of modern studies. It's not even a comparison. It's a completely different level of evidence and rigor.

Accreditation: How Bariatric Surgery Became Safer

Now I want to take a step back and talk about something that happened between 1991 and 2022 that fundamentally changed the safety of bariatric surgery. And that's the development of Centers of Excellence. Because one of the reasons bariatric surgery had a bad reputation in the early days wasn't just the procedures themselves — it was where and by whom they were being done.

In the late 1990s and early 2000s, when laparoscopic bariatric surgery exploded in popularity, the number of procedures skyrocketed. But so did complications. There were early reports showing 30-day mortality rates as high as 9% at low-volume centers. Nine percent. That means roughly 1 in 11 patients was dying within a month of surgery at some of these places.

The problem was clear: there were no standards for who could perform these operations or where they could be done. Any surgeon at any hospital could hang a shingle and start doing bariatric surgery. And some of them had no business doing it. Something had to change.

In November of 2003, the American Society for Bariatric Surgery — which is now the ASMBS — established the Surgical Review Corporation, or SRC, as an independent nonprofit entity for quality control. This was a big deal. They developed national standards using a meta-analysis of published data, a consensus conference at Georgetown University, and input from industry, insurance companies, and malpractice carriers. They created a two-tier designation system: provisional and full Center of Excellence.

And the growth was rapid. Within a few years, 135 hospitals and 265 surgeons had achieved full approval. And the data from those early centers was remarkable. Looking at the first 176 applicants — representing over 55,000 patients — the 90-day operative mortality rate was 0.35%. Compare that to the 9% at some low-volume centers. That's a 25-fold difference.

When this became available, I made sure that our practice was following all the evidence based protocols and we became an early center of approval. Over the next few years as I expanded to several different hospitals, I was able to get center of excellence designations at four different centers. I was so committed to the process that I became a reviewer for the society in order to review centers around the country and decide if they met approval or not.

This also gave me the ability to be involved in the creation of pediatric centers of excellence criteria. I remember sitting down in a hotel lobby with Neil hutcher, the head of the surgical review corporation and on the back of a napkin coming up with the first criteria for a pediatric center of excellence. We tried to discuss what differences in volume would mean and how to make sure that we could maintain quality at these lower volume pediatric centers.

Around the same time, the American College of Surgeons launched its own parallel accreditation program — the ACS Bariatric Surgery Center Network. So for a period, you had two separate accreditation programs running simultaneously. Which was a little confusing, but the point was the same: establish standards, improve safety.

Then in 2006, something important happened with Medicare. In November of 2005, the Centers for Medicare and Medicaid Services — CMS — had actually considered ending coverage for bariatric surgery in Medicare beneficiaries over 65. They were worried about safety.

But after advocacy from the ASMBS and others, CMS reversed course. In February of 2006, they published a National Coverage Decision saying they would cover bariatric surgery for Medicare beneficiaries with a BMI over 35 and at least one obesity-related comorbidity. But — and this is key — they required it be performed at an accredited Center of Excellence.

That was a watershed moment. It meant that if you wanted Medicare to pay for your bariatric surgery, you had to go to an accredited center. And that drove hospitals and surgeons to get accredited, which drove quality improvement across the board.

In 2012, the two accreditation programs merged. On April 1st, 2012, the ASMBS and the American College of Surgeons combined their programs into what's now called MBSAQIP — the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. Once again, I got involved and became a reviewer for this new program. I wanted to make sure that I understand all of the criteria inside and out and so that I can make sure that my program was at the front of any innovation and change.

Today, there are more than 900 MBSAQIP-accredited centers in the United States and Canada. More than 200,000 bariatric cases are captured annually in the MBSAQIP registry. And over 88% of all bariatric procedures in the US are now performed at accredited centers.

The evidence for accreditation is strong. A 2016 systematic review looked at 13 studies covering more than 1.5 million patients. Ten of the 13 studies showed a substantial benefit of accreditation. Mortality at accredited centers was more than three times lower than at non-accredited centers — 0.06% versus 0.22%. Morbidity was also reduced in the majority of studies.

But here's an ironic twist. Despite all of that evidence, in June of 2013, CMS concluded that there was — and I'm quoting — "not sufficient evidence" to continue requiring facility accreditation. And they dropped the Center of Excellence requirement.

The ASMBS surveyed its members. Over 80% voted to continue embracing accreditation voluntarily. And most private insurers still require or prefer accredited centers. But the fact that CMS walked it back — after the data clearly showed it was working — tells you something about how disconnected policy can be from evidence.

Pediatric Bariatric Surgery

Now let's talk about kids. And I know — the idea of bariatric surgery in children and teenagers makes a lot of people uncomfortable. I get it. But the data has evolved enormously, and this is an area where the gap between the evidence and the insurance criteria is especially wide.

Let's start with where we were. The 1991 NIH criteria explicitly stated — and I'm quoting — "no data available for adolescents." They were essentially excluded. Full stop.

And for years, that was the end of the conversation. If you were under 18, bariatric surgery wasn't even on the table. But over the following decades, two things happened. First, pediatric obesity rates skyrocketed. We went from childhood obesity being relatively uncommon to it being a public health crisis. Second, data started to accumulate. Surgeons began carefully performing bariatric surgery in adolescents, tracking outcomes, publishing results. And what they found was encouraging.

In 2018, the ASMBS published Best Practice Guidelines for pediatric bariatric surgery. They recommended surgery be considered for youth with a BMI of 35 or higher with severe comorbid disease, or a BMI of 40 or higher where comorbidities are commonly present but not mandatory. They also laid out clear contraindications — things like a medically correctable cause of obesity, untreated substance abuse, pregnancy, active eating disorder, or inability to adhere to postoperative recommendations.

Then in 2023, something really significant happened. The American Academy of Pediatrics — the AAP — published a landmark clinical practice guideline. This is the organization that represents pediatricians across the country. And they recommended referral for metabolic and bariatric surgery evaluation for adolescents 13 and older with severe obesity.

Their criteria were specific. For adolescents with Class 2 obesity — that's a BMI of 35 or higher, or 120% of the 95th percentile for age, whichever is lower — surgery should be considered if they have clinically significant comorbid conditions like type 2 diabetes, sleep apnea, fatty liver disease, or high blood pressure.

For adolescents with Class 3 obesity — BMI of 40 or higher, or 140% of the 95th percentile — comorbidities are not required. And the AAP was careful to emphasize that age alone is not the sole determinant. Physical and psychosocial maturity matter. And referral to a comprehensive multidisciplinary center doesn't automatically mean surgery — it means evaluation.

The 2022 ASMBS/IFSO guidelines formally included adolescents for the first time in international surgical society guidelines. And here's what's remarkable: the supporting evidence for pediatric surgery received a Grade A recommendation. That's the strongest level. Based on available data showing sustained efficacy and safety profiles comparable to adults.

So let me just put that timeline in perspective. In 1991: "No data available for adolescents." In 2022: Grade A recommendation — the strongest possible — for adolescent bariatric surgery. That's how much the evidence has evolved in 30 years.

I'm pleased to say that in 2022 I was able to publish my experience in adolescence and young adults where we had done over 300 at that time period we tracked down nearly 100 patients who had undergone surgery greater than 10 years prior. And found that these patients who had undergone A gastric bypass, at an average of 14 1/2 years, the average weight loss was still at 31.2%. An amazing number and testament to the longevity of bariatric surgery outcomes.

In addition, they had complete resolution of their comorbid conditions and the safety profile was also very acceptable. The great majority of the patients umm told me that they were extremely happy that they had undergone surgery and that it had completely changed their lives

And yet — — many insurance companies still impose higher BMI thresholds for adolescents. A survey of major insurers found that 43% of policies that cover adolescents require a BMI of 40 or higher with comorbidities. That's stricter than what any current guideline recommends. Not the ASMBS. Not the IFSO. Not the AAP. None of them.

These kids are being denied access to a treatment that every major medical organization says they should have access to. And the criteria being used to deny them aren't based on evidence. They're based on outdated assumptions and cost containment.

How Insurance Companies Play with the Criteria

Alright. Let's talk about the elephant in the room. Insurance companies. Because it's not just that insurers are using the 1991 criteria. It's that they've taken those criteria and added their own layers of requirements on top — many of which have absolutely no evidence base.

Let me walk you through what's actually happening. First, the basics. A survey of the 64 highest market share health insurance providers in the United States found that 92% still require a BMI of 40 or above, or 35 or above with a comorbidity. That's the 1991 criteria. Thirty-five years later. Ninety-two percent.

But here's where it gets worse. They don't just use the 1991 criteria as written. They've freelanced. Let's start with the supervised medical weight management requirement — what most people call the "diet history."

Eighty-seven percent of private insurers require a supervised medical weight management program before they'll approve surgery. That typically means 3 to 6 months of documented visits with a physician, showing that you've tried to lose weight through diet and exercise and it didn't work. Medicaid plans are even worse. They require an average of 6.6 months of supervised weight loss. Commercial plans average 3.8 months. Medicare and TriCare average about 1.7 months.

Now, you might think: well, that makes sense. You should try to lose weight before having surgery. Right? Here's the problem. A systematic review and meta-analysis looked at whether these insurance-mandated preoperative weight loss programs actually improve long-term outcomes after surgery. And the answer is no. They don't. The evidence does not support these programs' effectiveness at promoting long-term weight loss after surgery.

But you know what they do cause? Patient attrition. People drop out. They get discouraged. They can't make it to monthly appointments because of work, or childcare, or transportation. They lose their insurance. They give up. And they never get the surgery they need.

These programs may actually do more harm than good. That's not my opinion — that's what the systematic review concluded. Next: comorbidity requirements. Some insurers require documented comorbidities even at a BMI of 40 or above. Which, by the way, goes beyond even the 1991 NIH criteria. The 1991 criteria said BMI of 40 qualifies without comorbidities. Some insurance companies are stricter than a 35-year-old guideline that everyone agrees is outdated.

Then there's the one-surgery-per-lifetime issue. Some insurance companies are now limiting coverage to one bariatric procedure per lifetime. One. Ever.

This completely ignores the reality that obesity is a chronic, relapsing disease. Just like diabetes. Just like hypertension. You wouldn't tell a diabetic patient: "Sorry, we already gave you one medication. You don't get another one."

Revision surgery is sometimes medically necessary — for complications, for inadequate weight loss, for significant weight regain. A survey found that only 67% of policies would reimburse a second bariatric procedure for failure of weight loss. That means a third of insurers won't cover a revision even if the first surgery didn't work.

And then there are the adolescent restrictions we already talked about. Forty-three percent of policies that cover adolescents impose a higher BMI threshold than what any current guideline recommends. The number of pre-operative requirements ranges from 1 to 8 depending on the insurer. One to eight. There is no standardization. There is no consistency. It's a patchwork of arbitrary barriers that vary wildly from plan to plan, state to state.

And I want to be really clear about something. This is not evidence-based medicine. This is cost containment dressed up as clinical criteria. So why haven't insurers switched to the 2022 guidelines?

A few reasons. First, the 1991 NIH criteria carry the weight of a government institution. Even though the NIH itself says they're outdated, they still have that official stamp. The 2022 ASMBS/IFSO guidelines come from surgical societies — and insurers can dismiss them as "self-interested." Which is unfair, but it's the reality.

Second, expanding criteria means covering more patients. And covering more patients means more cost — at least in the short term. Never mind that bariatric surgery has been shown to reduce long-term healthcare costs. A systematic review found that compared to non-surgical treatment, bariatric surgery is actually cost-saving over a lifetime. The incremental cost-effectiveness ratio is about 18,000 to 46,000 dollars per quality-adjusted life year — well below most willingness-to-pay thresholds. But the short-term cost is what matters to the quarterly budget.

Third, there is no regulatory mechanism forcing insurers to update their criteria. Nobody is making them change. CMS has not updated its National Coverage Decision to reflect the 2022 guidelines. And until CMS moves, most private insurers won't either.

So here we are. In 2026. Using criteria from 1991. Based on data from the 1970s. With insurance companies adding their own non-evidence-based requirements on top. While every major medical and surgical organization in the world says it's time to change.

The Future: Beyond BMI

Alright. Let's look forward. Because even the 2022 guidelines — as much of an improvement as they are — still rely heavily on BMI. And BMI has some fundamental problems.

Let me explain. BMI is a simple ratio. Your weight in kilograms divided by your height in meters squared. That's it. It's a math equation. And it tells you... almost nothing about what's actually going on inside your body.

BMI can't tell you how much of your weight is muscle and how much is fat. It can't tell you where your fat is stored. And it turns out, where your fat is stored matters enormously.

Think about it this way. Two people can have the exact same BMI — let's say 34 — and have completely different health profiles. One person might carry most of their fat under their skin — what we call subcutaneous fat. That person might be metabolically healthy. Normal blood sugar. Normal blood pressure. Normal cholesterol.

The other person might carry most of their fat around their organs — what we call visceral fat. Visceral adipose tissue. And that person might have insulin resistance, pre-diabetes, fatty liver disease, high triglycerides, and be on a fast track to a heart attack. Same BMI. Completely different risk.

And this isn't just theory. Research published in the Journal of the American College of Cardiology shows that only about 11% of individual variability in insulin sensitivity can be explained by BMI. Eleven percent. That means 89% of what determines your metabolic risk has nothing to do with your BMI number.

Visceral fat — the fat around your organs — is the primary driver of metabolic disease. It's strongly associated with insulin resistance, type 2 diabetes, cardiovascular disease, fatty liver disease, and chronic inflammation. And here's something most people don't know — subcutaneous fat, the fat under your skin, is metabolically much less dangerous. In fact, some types of subcutaneous fat — like the fat in your legs and thighs — may actually be protective against heart disease. It traps fatty acids and keeps them from going to places they shouldn't be.

BMI can't tell the difference between any of this. It treats all weight the same. A pound of muscle, a pound of visceral fat, a pound of protective thigh fat — BMI doesn't care. It's all just weight divided by height. And that's a real problem when you're using it as the gatekeeper for life-changing surgery.

Now, the medical community is starting to recognize this. In 2023, the American Medical Association adopted a revised statement on BMI. They acknowledged — and I'm paraphrasing — that there are significant limitations with the widespread use of BMI in clinical settings, and that it should be used in conjunction with other measures like visceral fat, body composition, relative fat mass, and waist circumference. That's the AMA saying: BMI alone isn't enough.

And the ASMBS itself — the same organization that wrote the 2022 surgical guidelines — published a comprehensive review of body composition in 2025. And they said something really important. They said that body composition measurement provides a direct assessment of adiposity that can supplement BMI in the assessment of the bariatric surgery patient. They recommended that bariatric surgery programs consider adding DEXA scans — that's a type of body scan that can measure fat mass, lean muscle mass, and bone density — as part of the preoperative evaluation.

They also pointed out something really practical. For patients with Class 1 obesity — that's a BMI of 30 to 35 — body composition and metabolic assessment can identify a patient's individual phenotype. Meaning: are you metabolically healthy or metabolically unhealthy at that BMI? Because those with a metabolically unhealthy phenotype are at higher risk for cardiovascular events and therefore likely benefit more from surgery. Same BMI. Different risk. Different treatment plan.

And the science keeps coming.

A 2025 analysis of over 8,000 adults from the National Health and Nutrition Examination Survey — NHANES — found that visceral adipose tissue, measured by DEXA scan, was a strong predictor of metabolic syndrome, type 2 diabetes, and insulin resistance. They proposed a threshold of approximately 100 square centimeters of visceral fat as a sex-independent marker for metabolic disease risk. One number. Doesn't matter if you're male or female. Above 100 square centimeters of visceral fat, your metabolic risk goes up significantly.

MRI-based body composition studies from the UK Biobank — which is a massive research database of over 40,000 people — have shown that personalized fat scores, looking at visceral fat, subcutaneous fat, and liver fat separately, can identify high-risk obesity phenotypes regardless of BMI. Visceral fat adjusted for BMI was associated with increased risk of type 2 diabetes and coronary artery disease. Subcutaneous fat adjusted for BMI was largely neutral. And gluteofemoral fat — the fat in your hips and thighs — was actually associated with reduced risk. Three metabolically distinct fat depots. All invisible to BMI.

A 2026 study using AI-enabled CT scan analysis looked at bariatric surgery patients specifically. And they found that BMI and visceral fat are only weakly correlated. The R-squared was 0.237 — meaning BMI explained less than a quarter of the variation in visceral fat. And among patients with a BMI of 35 or higher, the correlation essentially disappeared. It was not statistically significant.

But here's the really interesting part. After surgery, visceral fat reduction showed a stronger association with time than BMI decline did. BMI plateaued at longer follow-up, but visceral fat kept dropping. In other words, the surgery was still doing its metabolic work — reducing the dangerous fat around the organs — even after the scale stopped moving. BMI missed that. Body composition analysis caught it.

And you don't always need fancy imaging to get a sense of someone's visceral fat burden. There's a simple clinical tool called the hypertriglyceridemic waist phenotype. You combine two things: waist circumference and triglyceride levels. If a man has a waist circumference of 90 centimeters or more and triglycerides of 177 milligrams per deciliter or more — or if a woman has a waist of 85 centimeters or more and triglycerides of 133 or more — there's about an 80% probability that person has excess visceral fat. You can assess that in any clinic, in about two minutes, without any imaging at all.

So what might the future look like? I think we're moving toward surgical candidacy criteria that incorporate several things beyond BMI. Fat mass and body fat percentage — not just total weight. How much of your body is actually fat, and how much is muscle and bone?

Visceral fat area — measured by DEXA, CT, MRI, or bioimpedance. Where is the fat? Is it around your organs, driving metabolic disease? Or is it under your skin, where it's relatively harmless?

Metabolic markers — things like insulin resistance measured by HOMA-IR, triglyceride levels, liver fat, inflammatory markers. What is the fat actually doing to your metabolism? And body composition phenotyping — are you metabolically healthy at your current weight, or metabolically unhealthy? Because that distinction matters more than the number on the scale.

There's already a framework for this. The American Association of Clinical Endocrinology has endorsed the concept of "adiposity-based chronic disease" — or ABCD. This framework defines obesity not by BMI alone, but by the amount, distribution, and function of adipose tissue and its resulting complications. It stages the disease based on the presence and severity of complications — not just how much you weigh.

And in 2025, the AACE updated their comprehensive obesity algorithm to emphasize that BMI conveys no direct information about the impact of excess adiposity on an individual's health. Treatment decisions — including surgery — should be driven by complication severity, not by BMI cutoffs alone.

The technology is getting there too. AI-enabled body composition analysis from routine CT scans — scans that patients are already getting for other reasons — can automatically measure visceral fat, subcutaneous fat, muscle mass, bone density, and liver fat. The technology exists right now. It's being validated. And it could eventually be integrated into the preoperative evaluation for every bariatric surgery candidate.

Imagine a future where the question isn't "Do you weigh enough to qualify?" but rather "Is your body composition and metabolic profile putting you at risk for disease? And would surgery change that trajectory?"

That's where we're headed. We're not there yet. These tools need more validation, more standardization, and more cost-effectiveness data before they replace BMI in insurance criteria. But the direction is clear. BMI alone is an inadequate gatekeeper for a surgery that treats metabolic disease. And the field is moving — slowly, but surely — toward precision obesity medicine.

The Bottom Line

Alright. Let's bring it all together. We've covered a lot of ground today. So let me walk you through the timeline one more time — because when you see it laid out, the gap between the evidence and the policy becomes impossible to ignore.

1991. A small panel — mostly non-surgeons — reviews a limited body of evidence from the era of open surgery and writes a consensus statement. BMI of 40, or 35 with comorbidities. Two procedures: gastric bypass and vertical banded gastroplasty. That statement legitimizes the field. And it freezes the criteria in place.

Late 1990s through the 2000s. Laparoscopic surgery transforms the field. Mortality drops tenfold. Sleeve gastrectomy emerges. VBG disappears. The field professionalizes.

2003. The ASMBS creates the Surgical Review Corporation and launches the first Center of Excellence program. Safety improves dramatically. 2006. CMS agrees to cover bariatric surgery for Medicare patients — but requires it be done at an accredited center.

2012. The two accreditation programs merge into MBSAQIP. Today, over 900 centers are accredited. Over 88% of all bariatric procedures happen at accredited facilities.

2013. Ironically, CMS drops the accreditation requirement — even though the data showed it was working. 2022. The ASMBS and IFSO finally publish updated guidelines. BMI threshold drops to 35 without comorbidities. BMI of 30 with metabolic disease. Asian thresholds adjusted. Adolescents included. Evidence base: hundreds of modern studies reviewed using rigorous PRISMA methodology.

2023. The American Academy of Pediatrics recommends bariatric surgery evaluation for adolescents 13 and older with severe obesity. The AMA acknowledges BMI's limitations. 2025. The ASMBS publishes a comprehensive review of body composition, recommending that DEXA and other tools supplement BMI in bariatric surgery evaluation. The AACE updates its obesity algorithm to emphasize complication-based staging over BMI cutoffs.

And today? 2026? Ninety-two percent of insurance companies still use the 1991 criteria. Eighty-seven percent still require supervised diet programs that don't improve outcomes. Some limit patients to one surgery per lifetime. And less than 1% of eligible patients actually receive the surgery that could change — or save — their lives.

So if you're watching this and you've been told you don't qualify for bariatric surgery — I want you to ask one question. By whose criteria? Because the criteria your insurance company is using may not reflect the current medical evidence. They may not reflect what the ASMBS says. Or the IFSO. Or the AAP. Or the ADA. Or the AACE. Or the AMA.

Advocate for yourself. Talk to your surgeon. Get a second opinion. Understand the guidelines — the real guidelines, the current ones — not the ones from 1991.

Obesity is a chronic, progressive, relapsing disease. It is not a failure of willpower. It is not a character flaw. It is a disease. And surgery is one of the most effective treatments we have for it. The evidence is overwhelming.

The field of bariatric surgery has evolved enormously over 35 years. The procedures are safer. The outcomes are better. The evidence is stronger. The criteria should evolve with it.

And someday — hopefully soon — they will. Thank you for watching. And if this was helpful, share it with someone who needs to hear it. And be sure to watch my next video where I'll cover differences between GLP1 medicines like... and surgery.

Real science. Real surgery. Real results.\